CHIP 2
Alternative Names: Antianaemic oral - Chiasma; CH 2; Chiasma Investigational Product 2; CHIP-2Latest Information Update: 10 Aug 2021
At a glance
- Originator Chiasma
- Class Antianaemics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 05 Aug 2021 Chiasma has been acquired by Amryt Pharma
- 28 Jul 2018 No recent reports of development identified for phase-I development in Anaemia in Israel (PO)
- 14 Oct 2015 Phase-I development is ongoing in Israel